[1] [2] Ozempic (off-label for weight): BMI 30, or BMI 2729.9 with a weight-related condition (hypertension, dyslipidemia, OSA, pre-diabetes, PCOS)
Unlike California and Pennsylvania, which provide broad coverage for all obesity-indicated GLP-1s, Kentuckys Medicaid program covers only Wegovy for weight management alongside Type 2 diabetes-indicated medications
Week-by-Week Progression Weight loss followed a predictable pattern across the 48-week study period: Week 12: Participants averaged 8.7% weight loss across all dose groups, with the 12mg group reaching 9.8%
GLP-1 receptor agonists improve insulin resistancea central driver of metabolic liver disease
#Obesity #GLP1 #Tirzepatide #Semaglutide #WeightManagement #ObesityMedicine #MetabolicHealth #ChronicDisease #Endocrinology #DiabetesCare This is spot on
After your first Wegovy dose, its normal to feel nothing, or just a little